The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CRUK: Phase II trial of ginisortamab with (1) 1st-line gemcitabine + nab-paclitaxel (AG) or (2) MEK inhibitor as maintenance therapy in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).
 
T.R. Jeffry Evans
Honoraria - Ascelia (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bristol Myers Squibb (Inst); CV6 Therapeutics (Inst); Eisai (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst); Seagen (Inst)
Speakers' Bureau - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Ewopharma (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst); United Medical (Inst)
Research Funding - Adaptimmune (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Athenex (Inst); Avacta Life Sciences (Inst); Basilea (Inst); Bayer (Inst); Beigene (Inst); Berg Pharma (Inst); Bicycle Therapeutics (Inst); BiolineRx (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Codiak BioSciences (Inst); CV6 Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Exscientia (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Immunocore (Inst); iOnctura (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); Lilly (Inst); Medivir (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MiNA Therapeutics (Inst); Moderna Therapeutics (Inst); Modulate Pharma (Inst); Novartis (Inst); Nucana (Inst); Nurix (Inst); Owkin (Inst); Pfizer (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Sierra Pharma (Inst); Sotio (Inst); Starpharma (Inst); T3 Pharmaceuticals (Inst); UCB (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - iOnctura (Inst); Medivir (Inst)
Travel, Accommodations, Expenses - Bristol Myers Squibb; Eisai; Merck Sharp & Dohme; Nucana; Pierre Fabre; Roche
Other Relationship - Genmab (Inst)
 
Tormod Guren
Consulting or Advisory Role - Incyte (Inst); Merck KGaA (Inst); SERVIER (Inst)
Speakers' Bureau - Amgen (Inst); Daiichi Sankyo (Inst); Pierre Fabre (Inst)
 
Mark Baxter
Honoraria - AstraZeneca; Bristol-Myers Squibb; Jazz Pharmaceuticals; Pfizer; SERVIER
Consulting or Advisory Role - AstraZeneca; SERVIER
Travel, Accommodations, Expenses - AstraZeneca; SERVIER
 
Alan Christie
Consulting or Advisory Role - AstraZeneca; Jazz Pharmaceuticals
Speakers' Bureau - AstraZeneca
Travel, Accommodations, Expenses - Jazz Pharmaceuticals
 
Fieke Froeling
Consulting or Advisory Role - Abbott Nutrition; Astellas Pharma; Pfizer; Viatris
Speakers' Bureau - SERVIER; SERVIER; Viatris
Research Funding - AstraZeneca (Inst); Sierra Oncology (Inst)
Travel, Accommodations, Expenses - Viatris
 
Angela Lamarca
Honoraria - Advanced Accelerator Applications; Advanz Pharma; AstraZeneca; Eisai; Incyte; Ipsen; Jazz Therapeutics; Merck; MSD Oncology; Novartis; Pfizer; QED Therapeutics; Roche; Servier; Taiho Oncology
Consulting or Advisory Role - Albireo Pharma; AstraZeneca/MedImmune; Boehringer Ingelheim; Boston Scientific; EISAI; GENFIT; Ipsen; MSD Oncology; Nutricia; QED Therapeutics; Roche; SERVIER; Taiho Pharmaceutical; TransThera Biosciences
Research Funding - Albireo Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); GENFIT (Inst); Ipsen; Jazz Therapeutics (Inst); Merck (Inst); Novartis (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); Roche (Inst); SERVIER (Inst); Taiho Oncology (Inst); TransThera Biosciences (Inst)
Travel, Accommodations, Expenses - Abbott Nutrition; Advanced Accelerator Applications; Advanz Pharma; Bayer; Celgene; Delcath Systems; Ipsen; Mylan; Novartis; Pfizer; Roche; Sirtex Medical
 
Fiona Collinson
No Relationships to Disclose
 
Robert Goldstein
No Relationships to Disclose
 
Teresa Macarulla
Consulting or Advisory Role - Ability Pharma; Advance Medical; Alligator Bioscience; Amgen; Aptitude Health; Arcus Biosciences; Astellas Pharma; AstraZeneca; Basilea; Baxter; BioLineRX; Boehringer Ingelheim; Celgene; Eisai; Ellipses Pharma; Esteve; Incyte; Ipsen; Janssen; Janssen; Lilly; Medscape; MFAR, Marketing Farmacéutico & Investigación Clínica; MSD; Novocure; Novocure; Paraxel; PEGASCY; Prime Oncology; QED Therapeutics; Revolution Medicines; Roche; Sanofi/Aventis; SERVIER; Taiho / Keylates; Zymeworks
Research Funding - Abbvie (Inst); Ability Pharma (Inst); Agios (Inst); Amc Medical Research (Inst); Amgen (Inst); Armo Biosciences (Inst); ASLAN Pharmaceuticals (Inst); ASTRAZENECA (Inst); Basilea Pharmaceutical (Inst); Bayer (Inst); Beigene (Inst); BiolineRx (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (BMS) (Inst); Cantargia AB (Inst); Celgene (Inst); Eisai (Inst); ERYTECH Pharma (Inst); Fibrogen (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Incyte (Inst); Ipsen (Inst); Keralty Group (Inst); Lilly (Inst); Loxo (Inst); Medimmune (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Millennium (Inst); Nelum Corp. (Inst); Novartis (Inst); Novocure (Inst); OncoMed (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Roche (Inst); VCN Biosciences (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celgene; H3 Biomedicine; Incyte; Merck; Prime Oncology; Sanofi; SERVIER
 
Paul Miller
No Relationships to Disclose
 
Debashis Sarker
Honoraria - Bayer; Eisai; Ipsen; SERVIER
Consulting or Advisory Role - AAA HealthCare; Abbvie; AstraZeneca; Bayer; Eisai; Incyte; Ipsen; MSD Oncology; Novartis; Pfizer; Roche; Sirtex Medical; UCB (Inst)
Speakers' Bureau - AstraZeneca; Bayer; Eisai; Incyte; SERVIER
Research Funding - Inspirata (Inst); UCB (Inst)
Travel, Accommodations, Expenses - Bayer; Boehringer Ingelheim; Ipsen
 
Gary Acton
No Relationships to Disclose
 
Josephine Salimu
No Relationships to Disclose
 
Sarah Potter
No Relationships to Disclose
 
Lefteris Kostaras
No Relationships to Disclose
 
Kathrin Heinzmann
No Relationships to Disclose
 
Paul Jones
Employment - UCB
Stock and Other Ownership Interests - UCB
 
Gustaf Rydevik
Employment - UCB
Stock and Other Ownership Interests - UCB
 
Barbara Koetz
Employment - Teva (I)
Consulting or Advisory Role - Adcendo; UCB
 
Sarah Halford
Consulting or Advisory Role - ISPEP; Medscape; Roche